|
1
|
He F, Fang Z, Shen C and Li L:
Meta-analysis of the effect of postoperative radiotherapy on
prognosis of prostatic cancer following radical prostatectomy. Int
J Clin Exp Med. 8:20589–20595. 2015.PubMed/NCBI
|
|
2
|
Zhang Q, Zhang C, Yang X, Yang B, Wang J,
Kang Y, Wang Z, Li D, Huang G, Ma Z, et al: Berberine inhibits the
expression of hypoxia induction factor-1alpha and increases the
radiosensitivity of prostate cancer. Diagn Pathol. 9:982014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mimeault M and Batra SK: Hypoxia-inducing
factors as master regulators of stemness properties and altered
metabolism of cancer- and metastasis-initiating cells. J Cell Mol
Med. 17:30–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li
Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced
aggressiveness of prostate cancer cells is linked with deregulated
expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
PLoS One. 7:e437262012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kitajima Y and Miyazaki K: The critical
impact of HIF-1a on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu F, Qi CL, Kong M, Liu TT, Li L and Li
BJ: Screening specific polypeptides of breast cancer stem cells
from a phage display random peptide library. Oncol Lett.
12:4727–4731. 2016.PubMed/NCBI
|
|
7
|
Jaworska D, Król W and Szliszka E:
Prostate cancer stem cells: Research advances. Int J Mol Sci.
16:27433–27449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bayin NS, Modrek AS, Dietrich A, Lebowitz
J, Abel T, Song HR, Schober M, Zagzag D, Buchholz CJ, Chao MV, et
al: Selective lentiviral gene delivery to CD133-expressing human
glioblastoma stem cells. PLoS One. 9:e1161142014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Labrecque MP, Takhar MK, Nason R,
Santacruz S, Tam KJ, Massah S, Haegert A, Bell RH, Altamirano-Dimas
M, Collins CC, et al: The retinoblastoma protein regulates
hypoxia-inducible genetic programs, tumor cell invasiveness and
neuroendocrine differentiation in prostate cancer cells.
Oncotarget. 7:24284–24302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu M, Wang X, McGregor N, Pienta KJ and
Zhang J: Dynamic regulation of Rad51 by E2F1 and p53 in prostate
cancer cells upon drug-induced DNA damage under hypoxia. Mol
Pharmacol. 85:866–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deep G and Panigrahi GK: Hypoxia-induced
signaling promotes prostate cancer progression: Exosomes role as
messenger of hypoxic response in tumor microenvironment. Crit Rev
Oncog. 20:419–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pellacani D, Packer RJ, Frame FM, Oldridge
EE, Berry PA, Labarthe MC, Stower MJ, Simms MS, Collins AT and
Maitland NJ: Regulation of the stem cell marker CD133 is
independent of promoter hypermethylation in human epithelial
differentiation and cancer. Mol Cancer. 10:942011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dey P, Velazquez-Villegas LA, Faria M,
Turner A, Jonsson P, Webb P, Williams C, Gustafsson JÅ and Ström
AM: Estrogen receptor β2 induces hypoxia signature of gene
expression by stabilizing HIF-1α in prostate cancer. PLoS One.
10:e01282392015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen H, Luo Z, Dong L, Tan Y, Yang J, Feng
G, Wu M, Li Z and Wang H: CD133/prominin-1-mediated autophagy and
glucose uptake beneficial for hepatoma cell survival. PLoS One.
8:e568782013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mak AB, Schnegg C, Lai CY, Ghosh S, Yang
MH, Moffat J and Hsu MY: CD133-targeted niche-dependent therapy in
cancer: A multipronged approach. Am J Pathol. 184:1256–1262. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Wang H, Cannon V, Wolcott KM, Song
H and Yates C: Side population rather than CD133(+) cells
distinguishes enriched tumorigenicity in hTERT-immortalized primary
prostate cancer cells. Mol Cancer. 10:1122011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reyes EE, Gillard M, Duggan R, Wroblewski
K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ,
et al: Molecular analysis of CD133-positive circulating tumor cells
from patients with metastatic castration-resistant prostate cancer.
J Transl Sci. 1:2015.doi: 10.15761/JTS.1000104. PubMed/NCBI
|
|
18
|
Park JJ, Jin YB, Lee YJ, Lee JS, Lee YS,
Ko YG and Lee M: KAI1 suppresses HIF-1α and VEGF expression by
blocking CDCP1-enhanced Src activation in prostate cancer. BMC
Cancer. 12:812012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang H, Benzonana LL, Zhao H, Watts HR,
Perry NJ, Bevan C, Brown R and Ma D: Prostate cancer cell
malignancy via modulation of HIF-1α pathway with isoflurane and
propofol alone and in combination. Br J Cancer. 111:1338–1349.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SO, Kim JS, Lee MS and Lee HJ:
Anti-cancer effect of pristimerin by inhibition of HIF-1α involves
the SPHK-1 pathway in hypoxic prostate cancer cells. BMC Cancer.
16:7012016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu CH, Tang WC, Sia P, Huang CC, Yang PM,
Wu MH, Lai IL and Lee KH: Berberine inhibits the metastatic ability
of prostate cancer cells by suppressing epithelial-to-mesenchymal
transition (EMT)-associated genes with predictive and prognostic
relevance. Int J Med Sci. 12:63–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
